CLDN9: A Potential Drug Target for Various Diseases (G9080)

Target Name: CLDN9

NCBI ID: G9080

CLDN9

Other Name(s): CLD9_HUMAN | claudin 9 | Claudin-9 | Claudin 9 | DFNB116

CLDN9: A Potential Drug Target for Various Diseases

CLDN9 (CLD9_HUMAN) is a protein that is expressed in the human placenta and has been identified as a potential drug target for various diseases, including cancer. CLDN9 has unique structure and is expressed in a specific cell type, making it a promising target for small molecule inhibitors.

CLDN9 is a transmembrane protein that is expressed in various tissues in the body, including the placenta, liver, and spleen. It is a member of the tight junction gene family (TJG), which includes several other proteins that are involved in cell-cell and cell-matrix tight junctions. CLDN9 is unique in that it is expressed in the placenta, which is a specialized tissue that is responsible for providing oxygen and nutrients to the developing fetus. The placenta is also the site of many diseases, including cancer, and therefore, CLDN9 may be a drug target or biomarker for these diseases.

CLDN9 is a protein that consists of 104 amino acids and has a molecular weight of 11.4 kDa. It has a unique structure, including a long extracellular domain that is involved in cell-cell tight junctions and a short intracellular domain that is involved in cell- matrix tight junctions. The long extracellular domain of CLDN9 consists of a catalytic center that is involved in the formation of tight junctions. This domain is known as the N-terminal transmembrane domain (NTD) and is responsible for the catalytic activity of the protein.

The short intracellular domain of CLDN9 is known as the C-terminal transmembrane domain (CTMD) and is responsible for the interaction with the placenta. This domain is known as the cytoplasmic tail (CTT) and is responsible for the stability and localization of the protein in the placenta.

CLDN9 has been shown to be involved in various physiological processes, including fetal development and placenta function. It has been shown to be involved in the formation of tight junctions, which are important for the proper functioning of cells in the body. tight junctions are also important for the regulation of cell-cell and cell-matrix interactions, which are critical for various physiological processes, including cell growth, migration, and adhesion.

In addition to its role in cell-cell and cell-matrix tight junctions, CLDN9 has also been shown to be involved in the regulation of various signaling pathways. It has been shown to be involved in the TGF-β pathway, which is a critical pathway for cell growth, differentiation, and survival. The TGF-β pathway is involved in the regulation of cellular processes that are critical for fetal development, including the formation of tissues and organs, and the regulation of cell-cell and cell-matrix interactions.

CLDN9 has also been shown to be involved in the regulation of the Wnt pathway, which is involved in the regulation of cell-cell interactions and the development of tissues. The Wnt pathway is important for the development and maintenance of various tissues, including the nervous system, endocrine system, and cardiovascular system.

In conclusion, CLDN9 is a unique protein that is expressed in the human placenta and is involved in various physiological processes, including fetal development and placenta function. Its unique structure, including the NTD and CTMD domains, makes it a potential drug target or biomarker for various diseases. Further studies are needed to determine the full function of CLDN9 and its potential as a drug target or biomarker.

Protein Name: Claudin 9

Functions: Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity

The "CLDN9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLDN9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets